Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2019/06/019535
CTRI/2019/06/019535
Active, not recruiting
Phase 4

Post-Marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis (Carfilzomib) in Indian Patients with Relapsed or Refractory Multiple Myeloma: A Prsopective, Open-Label, Non-Comparative, Multicentre Study

Amgen Technology Pvt Ltd0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: - Health Condition 2: C00-D49- Neoplasms

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: - Health Condition 2: C00-D49- Neoplasms
Sponsor
Amgen Technology Pvt Ltd
Status
Active, not recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Pms

Investigators

Sponsor
Amgen Technology Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • •The age limits are being captured as above for the purpose of this CTRI application.

Exclusion Criteria

  • •1\. Waldenström macroglobulinemia
  • •2\. Plasma cell leukemia
  • •3\. POEMS syndrome
  • •4\. Myelodysplastic syndrome
  • •5\. Primary amyloidosis
  • •6\. History of other malignancy within the past 5 years, with the following exception\[s]:
  • •Adequately treated non\-melanoma skin cancer or lentigo maligna without evidence of disease.
  • •Adequately treated cervical carcinoma in situ without evidence of disease.
  • •Adequately treated breast ductal carcinoma in site without evidence of disease.
  • •Prostatic intraepithelial neoplasia without evidence of prostate cancer.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 1
Study of B/F/TAF in Participants Switching from CAB + RPV to B/F/TAF for HIV-1 Infection.HIV-1 infectionMedDRA version: 20.1Level: LLTClassification code: 10068341Term: HIV-1 infection Class: 10021881Therapeutic area: Diseases [C] - Virus Diseases [C02]
CTIS2023-506660-13-00Gilead Sciences Inc.35
Completed
Phase 4
Post Marketing Study of Eribulin Mesylate in Patients with Breast CancerHealth Condition 1: C509- Malignant neoplasm of breast of unspecified siteHealth Condition 2: null- Patients with locally advanced or metastatic breast cancer, who have progressed after at least one regimens of chemotherapy which has included anthracycline and taxane therapy
CTRI/2018/03/012349Eisai Pharmaceuticals India Private Limited200
Active, not recruiting
Phase 4
To assess safety and effectiveness of Rivaroxaban(Xarelto)in managing coronary and or symptomatic peripheral artery disease in Indian PatientsHealth Condition 1: I251- Atherosclerotic heart disease of native coronary artery
CTRI/2022/01/039597Bayer Zydus Pharma Pvt Ltd
Active, not recruiting
Phase 1
Safety and tolerability of M254 in healthy volunteers and immune thrombocytopenic purpura (ITP) patientsImmune thrombocytopenic purpuraMedDRA version: 20.1Level: PTClassification code 10074667Term: Immune thrombocytopenic purpuraSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2018-003534-32-HUMomenta Pharmaceuticals, Inc.70
Completed
Phase 2
A 4-part Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 in healthy volunteers and in patients with immune thrombocytopenic purpura.
NL-OMON49624Momenta Pharmaceuticals, Inc.30